RSS   Newsletter   Contact   Advertise with us
Post Online Media

OptiNose appoints Keith Goldan as chief financial officer

OptiNoseOptiNose, a specialty biopharmaceutical company, announced the appointment of Keith A. Goldan as chief financial officer.

Mr. Goldan brings to the company more than 25 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.

Mr. Goldan is an experienced CFO of private and public biopharma companies from early stage through commercial stage, including Fibrocell, NuPathe, PuriCore (now Realm Therapeutics) and Biosyn.

He has led multiple M&A transactions, including NuPathe’s sale to Teva in 2014 and Biosyn’s sale to Cellegy in 2004.

Mr. Goldan’s experience also includes a variety of roles with ViroPharma; Century Capital Associates, a specialty consulting firm with a focus on capital strategy for healthcare clients; and the Healthcare & Life Sciences Practice of KPMG.

Mr. Goldan holds a BS (cum laude) in finance from the Robert H. Smith School of Business at the University of Maryland and an MBA from the Wharton School of Business at the University of Pennsylvania.


 LATEST MOVES FROM Pennsylvania 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy